• Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. (wikipedia.org)
  • ReoPro Abciximab" (PDF). (wikipedia.org)
  • Fass environmental information for ReoPro (abciximab) from Janssen (downloaded 2019-09-04). (janusinfo.se)
  • Reopro (generic name: abciximab), Integrilin (generic name: eptifibatide) and Aggrastat (generic name: tirofiban) are all platelet-inhibiting drugs used in cardiac care. (isixsigma.com)
  • The control group (n=72) comprised of patients who had undergone conventional PCI technique before the routine availability of distal embolic protection devices, with balloon pre-dilatation of the target lesion followed by stent deployment and optional use of intragraft verapamil or intravenous abciximab. (eurekaselect.com)
  • We investigated whether there are differences in the degree of GP IIb/IIIa receptor occupancy and platelet inhibition in blood drawn from the coronary sinus (CS) shortly after intracoronary versus intravenous abciximab bolus administration. (uni-luebeck.de)
  • Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane. (wikipedia.org)
  • Many of the side effects of abciximab are due to its anti-platelet effects which increase the risk of bleeding. (wikipedia.org)
  • Blockade of the platelet glycoprotein IIb/IIIa receptor by abciximab (c7E3 Fab) during coronary intervention reduces the incidence of ischemic complications, but has been associated with a doubling of the risk for bleeding complications. (houstonmethodist.org)
  • Reduction and weight adjustment of heparin dose and early sheath removal in the setting of platelet inhibition with abciximab during coronary intervention may be useful in diminishing the incidence of hemorrhagic complications without loss of clinical efficacy. (houstonmethodist.org)
  • Background: In patients with ST-elevation myocardial infarction (STEMI), direct intracoronary bolus administration of the glycoprotein (GP) IIb/IIIa receptor antagonist abciximab is associated with a reduction in infarct size, better myocardial salvage, less microvascular obstruction and improved myocardial blush grade as compared to intravenous bolus injection, presumably caused by higher local drug concentrations leading to a more pronounced inhibition of platelet aggregation. (uni-luebeck.de)
  • We investigated, whether GPVI-Fc added in vitro on top of acetylsalicylic acid (ASA), the P2Y 12 antagonist ticagrelor, and the fibrinogen receptor antagonist abciximab alone or in combination would increase inhibition of platelet activation by atherosclerotic plaque. (thieme-connect.com)
  • GPVI-Fc added on top of abciximab, a clinically used anti-fibrinogen receptor antibody which blocks platelet aggregation, strongly inhibited total (81%) and stable (89%) platelet adhesion. (thieme-connect.com)
  • Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive molecules. (smpdb.ca)
  • One hundred three patients undergoing coronary intervention received abciximab (0.25 mg/kg bolus, 10 μg/min infusion for 12 hours) and aspirin and were randomized by a 2 x 2 factorial design to 1 of 2 weight-adjusted heparin doses and to 1 of 2 strategies for heparin discontinuation and vascular sheath removal. (houstonmethodist.org)
  • in the 'early sheath removal' group, heparin was stopped after the interventional procedure and sheaths were removed during the abciximab infusion. (houstonmethodist.org)
  • The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure and a decreased need for repeated coronary artery revascularization in the first month following the procedure. (wikipedia.org)
  • We did a randomised, open-label trial to compare the efficacy and safety of tenecteplase plus enoxaparin or abciximab, with that of tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction. (nyu.edu)
  • The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators 2001, ' Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction ', Lancet , vol. 358, no. 9282, pp. 605-613. (nyu.edu)
  • The present pilot study investigated whether modification of heparin dosing and/or early sheath removal would reduce the hemorrhagic complications associated with abciximab. (houstonmethodist.org)
  • four of these resolved (one partial, three complete) following treatment with abciximab and/or heparin during the procedure. (surgicalneurologyint.com)
  • Abciximab does not require dose adjustments for patients with kidney failure. (wikipedia.org)
  • Patients in the novel strategy group received prophylactic intra-graft administration of abciximab and verapamil followed by direct stenting (n=91). (eurekaselect.com)
  • The therapeutic efficacy of Prothrombin can be decreased when used in combination with Abciximab. (drugbank.com)
  • Investigating Abciximab (a GP IIb-IIIa inhibitor) in combination with rapid access to cardiac cath. (duke.edu)
  • This page shows results related to Abciximab and Cardiac Procedure Complication from the FDA Adverse Event Reporting System (AERS). (drugcite.com)
  • Share your experience with Abciximab and Cardiac Procedure Complication. (drugcite.com)
  • Abciximab induced thrombocytopenia is usually rapid occurring hours after administration but may occur up to 16 days later. (wikipedia.org)
  • In carefully selected subgroup of SVG lesions without visible macrothrombus, a strategy of prophylactic intra-graft administration of abciximab and verapamil, combined with direct stenting of the graft lesion without pre-dilatation, can be safely accomplished without any significant risk of slow-flow/no-reflow phenomenon. (eurekaselect.com)
  • Transfusing platelets is the only known treatment for abciximab-induced thrombocytopenia, but this therapy may have limited effectiveness because the drug may bind and inhibit the receptors on the newly transfused platelets. (wikipedia.org)
  • To learn more about all adverse events for Abciximab, view the complete Abciximab adverse event report . (drugcite.com)
  • Share your experience with Abciximab and Blood Glucose Increased. (drugcite.com)
  • 8. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. (nih.gov)
  • Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. (nih.gov)
  • Abciximab, ReoPro ® , is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. (nih.gov)
  • The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure and a decreased need for repeated coronary artery revascularization in the first month following the procedure. (wikipedia.org)
  • In a "high-risk" population, abciximab also reduced the need for target lesion revascularization. (medscape.com)
  • A 68% reduction in composite in-hospital cardiac events (i.e., death, myocardial infarction, urgent revascularization) was observed in the abciximab group (3.7% versus 11.5%, p = 0.1). (medscape.com)
  • Recent large randomized trials have shown that abciximab [a potent inhibitor of platelet aggregation via glycoprotein (GP) IIb/IIIa blockade] is a safe and effective drug in reducing the incidence of death, myocardial infarction and the need for urgent revascularization after percutaneous transluminal coronary balloon angioplasty or coronary stent deployment. (medscape.com)
  • [ 1 , 2 ] Furthermore, the use of abciximab in "high-risk" coronary angioplasty was associated with a significant reduction in target lesion revascularization at 6-month [ 3 ] and 3-year follow-up. (medscape.com)
  • Although prophylactic administration of abciximab has been demonstrated to improve clinical outcomes in patients having elective or unplanned coronary stent deployment and reduces target vessel revascularization in stented patients with diabetes mellitus, the utility of abciximab in patients undergoing stenting for long coronary stenoses is unknown. (medscape.com)
  • Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. (wikipedia.org)
  • Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane. (wikipedia.org)
  • Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. (nih.gov)
  • PURPOSE: To report intermediate results of a pilot study in which the glycoprotein IIb/IIIa receptor antagonist abciximab was given to patients during percutaneous carotid stenting for recurrent internal carotid artery (ICA) stenosis. (keyopinionleaders.com)
  • General - Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. (nih.gov)
  • Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. (nih.gov)
  • Pre-clinical experience- Maximal inhibition of platelet aggregation was observed when ≥ 80% of GPIIb/IIIa receptors were blocked by Abciximab. (nih.gov)
  • In non-human primates, Abciximab bolus doses of 0.25 mg/kg generally achieved a blockade of at least 80% of platelet receptors and fully inhibited platelet aggregation. (nih.gov)
  • Pharmacodynamics- Intravenous administration in humans of single bolus doses of Abciximab from 0.15 mg/kg to 0.30 mg/kg produced rapid dose-dependent inhibition of platelet function as measured by ex vivo platelet aggregation in response to adenosine diphosphate (ADP) or by prolongation of bleeding time. (nih.gov)
  • Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. (ru.nl)
  • Therefore, the aim of the current study was to perform a meta-analysis of randomized trials (RCTs) to assess the clinical efficacy and safety of IC vs IV abciximab administration in STEMI patients undergoing primary angioplasty. (ru.nl)
  • While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. (wikipedia.org)
  • Abciximab also binds to the vitronectin (α v β 3 ) receptor found on platelets and vessel wall endothelial and smooth muscle cells. (nih.gov)
  • Abciximab binds with similar affinity to the vitronectin receptor, also known as the α v β 3 integrin. (nih.gov)
  • 80% GPIIb/IIIa receptor blockade, but above the in vivo therapeutic range, Abciximab more effectively blocked the burst of thrombin generation that followed platelet activation than select comparator antibodies which inhibit GPIIb/IIIa alone (1). (nih.gov)
  • Abciximab also binds to the activated Mac-1 receptor on monocytes and neutrophils (2). (nih.gov)
  • In in vitro studies, Abciximab and 7E3 IgG blocked Mac-1 receptor function as evidenced by inhibition of monocyte adhesion (3). (nih.gov)
  • Doses of the murine version of 7E3 or Abciximab sufficient to produce high-grade (≥ 80%) GPIIb/IIIa receptor blockade prevented acute thrombosis and yielded lower rates of thrombosis compared with aspirin and/or heparin. (nih.gov)
  • Intravenous administration of a 0.25 mg/kg bolus dose of Abciximab followed by continuous infusion of 10 μg/min (or a weight-adjusted infusion of 0.125 μg/kg/min to a maximum of 10 μg/min) produces approximately constant free plasma concentrations throughout the infusion. (nih.gov)
  • BACKGROUND: Adjunctive abciximab administration has been demonstrated to reduce mortality and reinfarction in patients with ST-elevation myocardial infarction (STEMI) referred to invasive management. (ru.nl)
  • CONCLUSIONS: The present updated meta-analysis showed that IC administration of abciximab is associated with significant benefits in myocardial perfusion, but not in clinical outcome at short-term follow-up as compared to IV abciximab administration, without any excess of major bleedings in STEMI patients undergoing primary PCI. (ru.nl)
  • aspirin rectal increases effects of abciximab by pharmacodynamic synergism. (medscape.com)
  • aspirin, abciximab. (medscape.com)
  • aspirin/citric acid/sodium bicarbonate, abciximab. (medscape.com)
  • A drug called abciximab was administered intravenously during the procedure, and clopidogrel was given orally for at least 12 months after the procedure, accompanied by aspirin for those who could tolerate it. (nih.gov)
  • Pharmacokinetics- Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors. (nih.gov)
  • We characterized patients undergoing elective implantation of long or multiple overlapping coronary stents and determined the impact of abciximab administration on clinical and angiographic outcomes. (medscape.com)
  • Se usa en el tratamiento de la angina inestable resistente al tratamiento y para la prevención de las complicaciones isquémicas en pacientes que se someten a intervenciones coronarias percutáneas como la ANGIOPLASTIA, la ATERECTOMÍA o la implantación de stents. (bvsalud.org)
  • Transfusing platelets is the only known treatment for abciximab-induced thrombocytopenia, but this therapy may have limited effectiveness because the drug may bind and inhibit the receptors on the newly transfused platelets. (wikipedia.org)
  • The inhibitory effects of Abciximab were substantially reversed by the transfusion of platelets in monkeys. (nih.gov)
  • moreover, abciximab improves 6-month clinical and angiographic outcomes in such a complex setting. (medscape.com)
  • No information is available on the clinical use of abciximab during breastfeeding. (nih.gov)
  • Experimental studies and small clinical trials suggest the superiority of intracoronary (IC) injection of abciximab over IV route. (ru.nl)
  • Each single use vial contains 2 mg/mL of Abciximab in a buffered solution (pH 7.2) of 0.01 M sodium phosphate, 0.15 M sodium chloride and 0.001% polysorbate 80 in Water for Injection. (nih.gov)
  • The antithrombotic efficacy of prototype antibodies [murine 7E3 Fab and F(ab´) 2 ] and Abciximab was evaluated in dog, monkey and baboon models of coronary, carotid, and femoral artery thrombosis. (nih.gov)
  • However, we observed a significant relationship between patient's risk profile and mortality benefits from IC abciximab administration (p=0.011). (ru.nl)
  • Because abciximab is a large protein molecule with a molecular weight of 47,615 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. (nih.gov)
  • Abciximab does not require dose adjustments for patients with kidney failure. (wikipedia.org)
  • Therefore, waiting for long-term follow-up results and additional randomized trials, IC abciximab administration cannot be routinely recommended, but may be considered in high-risk patients. (ru.nl)
  • Many of the side effects of abciximab are due to its anti-platelet effects which increase the risk of bleeding. (wikipedia.org)
  • In in vitro studies using a model cell line derived from melanoma cells, Abciximab blocked α v β 3 -mediated effects including cell adhesion (IC 50 = 0.34 μg/mL). (nih.gov)
  • acalabrutinib increases effects of abciximab by anticoagulation. (medscape.com)
  • Until more data become available, abciximab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. (nih.gov)
  • Abciximab has a plasma half-life of about ten minutes, with a second phase half-life of about 30 minutes. (wikipedia.org)